实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (2): 241-244.doi: 10.3969/j.issn.1672-5069.2018.02.021

• 肝硬化 • 上一篇    下一篇

内镜下套扎联合硬化剂注射治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者疗效及其再出血危险因素分析*

倪猛, 张海洋   

  1. 473000 河南省南阳市中心医院消化内科一病区(倪猛); 普外科(张海洋)
  • 收稿日期:2017-07-19 出版日期:2018-03-10 发布日期:2018-03-19
  • 作者简介:倪猛,男,40岁,大学本科,副主任医师。研究方向:消化系统疾病诊治及内镜下治疗研究。E-mail:eddwan765@163.com
  • 基金资助:
    *河南省自然科学基金资助项目(编号:0611044800)

Clinical efficacy of endoscopic variceal ligation combined with sclerotherapy in the treatment of patients with hepatitis B liver cirrhosis and esophageal variceal bleeding

Ni Meng, Zhang Haiyang   

  1. Department of Gastroenterology,Central Hospital,Nanyang 473000,Henan Province,China
  • Received:2017-07-19 Online:2018-03-10 Published:2018-03-19

摘要: 目的 研究内镜下套扎联合硬化剂注射治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血(EGVB)患者的疗效,并分析引起治疗后再出血的危险因素。 方法 2012年2月~2016年2月收治的120例乙型肝炎肝硬化并发EGVB患者,采用内镜下食管静脉曲张套扎术(EVL)联合内镜下静脉曲张硬化剂注射术(EIS)治疗,对胃底静脉曲张出血患者采用组织黏胶内镜下注射联合EIS治疗,术后给予心得安治疗。采用Logistic回归分析再出血的危险因素。 结果 在手术过程中止血成功率为100.0%,33例EGVB1型患者治疗后静脉曲张消失率明显高于而静脉曲张复发率显著低于2型或1型/2型患者(P<0.05);不同类型静脉曲张患者治疗后再出血率比较无显著性差异(P>0.05);35例再出血患者男性占(85.7%),明显高于85例未再出血组的49.4%(P<0.05),年龄明显大于未出血患者(P<0.05),门静脉内径和Child-Pugh评分分别为(1.5±0.5)cm和(10.3±2.1)分,显著高于未出血患者[分别为(1.1±0.2) cm和(7.3±1.3) 分,P<0.05],而血清白蛋白和血钠浓度分别为(23.4±5.5) g/L和(124.67±31.47) mmol/L,显著低于未出血患者[(33.6±6.7)g/L和(137.5±36.2) mmol/L,P<0.05];经Logistic回归分析,发现门静脉内径和Child-Pugh评分是诱发再出血的危险因素[OR=3.713(1.253~10.999)、OR=4.267(1.311~13.886)],而白蛋白水平和血钠浓度是再出血发生的保护因素[OR=0.236(0.062~0.902)、OR=0.143(0.026~0.785)]。 结论 内镜下套扎联合硬化剂注射治疗乙型肝炎肝硬化并发EGVB患者临床疗效显著,并且对EGVB1型患者疗效最好。门静脉内径宽或Child-Pugh评分高说明肝储备功能差,发生再出血的风险就大。因此,针对这样的患者,更应该做好防治再出血治疗。

关键词: 肝硬化, 食管胃底静脉曲张破裂出血, 内镜下套扎, 硬化剂注射, 组织黏胶注射, 再出血

Abstract: Objective To investigate the clinical efficacy of endoscopic variceal ligation combined with sclerotherapy in the treatment of patients with hepatitis B liver cirrhosis complicated by esophageal and gastric varices bleeding (EGVB). Methods 120 patients with hepatitis B liver cirrhosis and EGVB between February 2012 and February 2016 were recruited in our hospital. The clinical data of patients were retrospectively analyzed. Esophageal variceal bleeding were treated by endoscopic variceal ligation (EVL) combined with endoscopic variceal sclerotherapy (EIS) and gastric variceal bleeding were treated with endoscopic injection of tissue adhesive combined with EIS treatment. Propranolol was given post-operational. The clinical efficacy and risk factors of rebleeding were analyzed. Results The success rate of hemostasis was 100.0% in our series;the varices disappeared in 90.9% of patients with EGVB types one,significantly higher than 66.7% in with type two or 69.4% in with type one/two;the variceal recurrence rate in EGVB type one was significantly lower than those in patients with type one/two or type two(P<0.05);after treatment,the rates of rebleeding in patients with different types of varices showed no significant difference(P>0.05);the proportion of male and aged >65 yr in 35 patients with rebleeding were 85.7% and 31.4%,respectively,significantly higher than 49.4% and 14.1%(P<0.05) in 85 patients without rebleeding,the portal vein diameter and Child-Pugh scores were(1.5±0.5)cm and (10.3±2.1),respectively,significantly wider or higher than (1.1±0.2) cm and [(7.3±1.3),respectively,P<0.05] in patients without rebleeding; serum albumin level and serum sodium concentration in rebleeding group were (23.4±5.5) g/L and (124.67±31.47) mmol/L,significantly lower than [(33.6±6.7) g/L and(137.5±36.2) mmol/L,respectively,P<0.05] in patients without rebleeding;Logistic regression analysis showed that the portal vein diameter[OR=3.713 (1.253~10.999)] and Child-Pugh score[OR=4.267(1.311~13.886)] were the independent risk factors for rebleeding after operation,and the blood albumin level [OR=0.236(0.062~0.902)] and sodium concentration [OR=0.143(0.026~0.785)] were the protective factors for rebleeding. Conclusion Endoscopic variceal ligation combined injection of sclerosing agent in the treatment of patients with hepatitis B liver cirrhosis with EGVB can get a good significantly clinical curative efficacy and the best efficacy in patients with EGVB type one. The diameter of portal vein and Child-Pugh score are the independent risk factors in forecasting rebleeding in patients with hepatitis B cirrhosis complicated by EGVB after endoscopic treatment.

Key words: Liver cirrhosis, Esophageal and gastric varices bleeding, Endoscopic variceal ligation, Sclerotherapy, Histoacryl injection, Rebleeding